Key result
Tibolone significantly improved depression (HAM-D score 10.2 vs 16.17) and climacteric symptoms (GCS score 20.30 vs 23.33) compared to escitalopram at 12 weeks in postmenopausal women.
Why the study?
A high prevalence of psychiatric disorders, particularly depressive and anxiety disorders, is observed among women throughout the postmenopausal stage.
Does tibolone improve depression, climacteric symptoms, and sexual functioning compared to escitalopram in postmenopausal women with depression?
Does tibolone improve depression, climacteric symptoms, and sexual functioning compared to escitalopram in postmenopausal women with depression?
Tibolone may be more effective than escitalopram in improving depression, climacteric symptoms, and sexual functioning in postmenopausal women.
Tibolone may warrant consideration alongside antidepressants for postmenopausal depression with climacteric symptoms; leaves open need for blinded RCTs before practice change.
Background: A high prevalence of psychiatric disorders, particularly depressive and anxiety disorders among women is observed through the postmenopausal stage. Aim: The aim of this study is to compare the safety and efficacy of tibolone (TIB) and escitalopram (ESCIT) in postmenopausal women (PMW). Materials and Methods: It was an interventional, open-label, hospital-based, follow-up study conducted on 60 PMW with the diagnosis of depression as per the Diagnostic and Statistical Manual of Mental Disorder-5 criteria. Patients were divided into two groups of 30 each, i.e. Group I (TIB-2.5 mg/day) and Group II (ESCIT-10–20 mg/day). The primary outcome was assessed for change in climacteric symptom scores on Greene's Climacteric Scale (GCS), severity of depression and anxiety on Hamilton Rating Scale for Depression (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A), and sexual functioning on Arizona Sexual Experience Scale (ASEX). The secondary outcome of well-being was assessed on World Health Organization Quality of life (QOL)-BREF. All the observations were carried out from baseline and at 2, 4, 8, and 12 weeks. Results: Both the groups showed significant improvement in climacteric and depressive symptoms. However, at the 8 th and 12 th weeks, mean ± standard deviation scores were significantly lower in Group I (GCS score - 24.80 ± 4.92, 20.30 ± 3.56; HAM-D score - 16.57 ± 5.83, 10.2 ± 5.67) compared to Group II (GCS score - 27.27 ± 5.83 and 23.33 ± 5.70, HAM-D score - 19.97 ± 7.98 and 16.17 ± 10.11). No significant difference between the groups was seen for anxiety on HAM-A scores. Only in Group I, there was significant improvement in ASEX scores. QoL in Group I had shown significant improvement in physical and psychological domain compared to Group II at different time interval, i.e. 4 th and 8 th week onward. In Group I, Alternative Dispute Resolution was reported to be 23.3%, whereas it was 56.7% in Group II. However, none were serious to warrant discontinuation. Conclusion: TIB was better than ESCIT in improving depression, climacteric symptoms, and physical and psychological domain of QoL with an additional benefit of restoring sexual functioning.
No takes yet. Share an insight, caveat, or question.
Raj et al. (2021) studied Depression in postmenopausal women (n=60). Tibolone vs. Escitalopram (10-20 mg/day) was evaluated on Change in climacteric symptom scores on Greene's Climacteric Scale (GCS), severity of depression and anxiety on HAM-D and HAM-A, and sexual functioning on ASEX. Tibolone significantly improved depression (HAM-D score 10.2 vs 16.17) and climacteric symptoms (GCS score 20.30 vs 23.33) compared to escitalopram at 12 weeks in postmenopausal women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: